June 4, 2009 - Lantheus Medical Imaging Inc. said today the company’s leading imaging agent, Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease.
The results of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), will be presented by the University of Pittsburgh Graduate School of Public Health at a special symposium from 4:15 - 5:15 p.m. (CT) Sunday, June 7, at the American Diabetes Association 69th Scientific Sessions in New Orleans.
In the study, SPECT myocardial perfusion imaging (MPI) with Cardiolite was used to objectively identify coronary artery disease during initial patient recruitment and for subsequent one, three and five-year follow-up of patients enrolled in the study to determine the impact of therapy on left ventricular ejection fraction (LVEF), ischemic burden and scar. One of the two primary objectives for the BARI 2D study was to determine if a strategy of initial elective coronary revascularization combined with aggressive medical therapy results in a lower five-year mortality compared with a strategy of initial aggressive medical therapy alone. Lantheus Medical Imaging provided support for the study.
For more information: www.cardiolite.com
September 09, 2026 
